Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortinovis, Diego Luigi, Colonese, Francesca, Abbate, Maria Ida, Sala, Luca, Meazza Prina, Marco, Cordani, Nicoletta, Sala, Elisa, Canova, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751403/
https://www.ncbi.nlm.nih.gov/pubmed/36530878
http://dx.doi.org/10.3389/fmed.2022.989405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751403/
https://www.ncbi.nlm.nih.gov/pubmed/36530878
http://dx.doi.org/10.3389/fmed.2022.989405

Ejemplares similares